SCLX

+ Watchlist + Portfolio

Scilex Holding Company

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.40
52-Week Range: $2.62 – $16.81
Market Cap: $28.56M
P/E (TTM): —
EPS (TTM): -49.70
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -105.83%
Gross Margin: 55.50%
Operating Margin: -385.02%
Profit Margin: 0.00%
Current Ratio: 0.07
Debt/Equity: —
Total Debt: $105.98M
Free Cash Flow: $-8.84M
Revenue Growth: -22.80%
Earnings Growth: —
Enterprise Value: $131.80M

SCLX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$38.03M	$46.74M	$56.59M	$30.25M
Cost of Revenue	$10.80M	$15.68M	$16.69M	$10.60M
Gross Profit	$27.24M	$31.06M	$39.90M	$19.65M
Research & Development	$9.05M	$12.75M	$9.64M	$20.71M
Selling, General & Admin	$64.89M	$119.64M	$119.02M	$266.88M
Operating Expenses	$77.87M	$136.49M	$132.69M	$291.96M
Operating Income	-$50.63M	-$105.43M	-$92.79M	-$272.30M
EBITDA	-$9.79M	-$109.10M	-$66.80M	-$357.94M
Pretax Income	-$23.36M	-$114.32M	-$72.81M	-$374.03M
Income Tax	$4.00K	$13.00K	-$1.00K	$26.00K
Net Income	-$23.36M	-$114.33M	-$72.81M	-$358.73M
Diluted EPS	-5.95	-44.80	-8.05	-36.48
Diluted Shares	3.84M	3.72M	10.14M	11.03M

SCLX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.18M	$3.92M	$3.27M	$4.96M
Receivables	$21.24M	$34.60M	$26.44M	$15.24M
Inventory	$1.38M	$4.21M	$2.44M	$4.79M
Current Assets	$29.61M	$46.78M	$41.55M	$38.36M
Total Assets	$86.53M	$101.31M	$92.95M	$364.98M
Current Liabilities	$44.84M	$250.38M	$259.63M	$483.65M
Long-Term Debt	—	$17.04M	$845.00K	$22.48M
Total Debt	$1.41M	$128.46M	$37.96M	$124.14M
Total Liabilities	$50.29M	$274.25M	$285.60M	$576.73M
Retained Earnings	-$375.91M	-$490.25M	-$563.05M	-$921.79M
Shareholders' Equity	$36.24M	-$172.94M	-$192.64M	-$207.78M
Working Capital	-$15.23M	-$203.60M	-$218.09M	-$445.29M
Net Debt	—	$121.55M	$32.45M	$104.30M

SCLX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$21.26M	-$20.71M	$19.35M	$3.82M
Capital Expenditure	-$2.07M	-$330.00K	-$600.00K	-$733.00K
Free Cash Flow	-$23.32M	-$21.04M	$18.75M	$3.08M
Depreciation & Amortisation	$3.96M	$4.15M	$4.05M	$4.62M
Stock-Based Compensation	$5.28M	$14.60M	$15.69M	$15.49M
Investing Cash Flow	-$2.07M	-$330.00K	-$2.67M	$4.08M
Financing Cash Flow	$21.17M	$23.58M	-$18.13M	-$5.46M
Share Repurchases	$0.00	-$10.00M	$0.00	—
Net Change in Cash	-$2.15M	$2.54M	-$1.46M	$2.44M

SCLX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$5.00M	$9.90M	$10.56M	$4.79M	$8.61M	$7.64M
Cost of Revenue	$1.38M	$3.27M	$3.33M	$2.61M	$4.45M	$3.68M
Gross Profit	$3.62M	$6.62M	$7.23M	$2.18M	$4.17M	$3.96M
Research & Development	$2.46M	$6.19M	$3.90M	$8.17M	$3.21M	$3.34M
Selling, General & Admin	$28.06M	$19.84M	$188.82M	$30.16M	$31.03M	$27.96M
Operating Expenses	$31.52M	$27.04M	$193.74M	$39.66M	$36.34M	$33.39M
Operating Income	-$27.90M	-$20.41M	-$186.51M	-$37.48M	-$32.17M	-$29.42M
EBITDA	-$26.89M	-$40.34M	-$254.00M	-$41.01M	-$29.30M	-$106.04M
Pretax Income	-$26.08M	-$44.03M	-$257.82M	-$46.10M	-$45.65M	-$114.98M
Income Tax	—	$19.00K	$1.00K	$6.00K	—	$7.00K
Net Income	-$26.08M	-$42.31M	-$257.23M	-$33.11M	-$43.27M	-$113.50M
Diluted EPS	-2.26	-7.42	-22.17	—	-6.28	-16.65
Diluted Shares	11.56M	11.60M	11.60M	—	6.89M	6.89M

SCLX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.80M	$4.10M	$878.00K	$4.96M	$3.35M	$566.00K
Receivables	$10.62M	$16.77M	$11.94M	$15.24M	$29.85M	$25.64M
Inventory	$3.02M	$2.52M	$1.08M	$4.79M	$4.53M	$4.17M
Current Assets	$28.70M	$33.67M	$16.49M	$38.36M	$41.97M	$36.23M
Total Assets	$78.98M	$83.75M	$275.88M	$364.98M	$293.63M	$253.56M
Current Liabilities	$275.74M	$305.93M	$358.95M	$483.65M	$501.75M	$512.24M
Long-Term Debt	—	—	—	$22.48M	—	—
Total Debt	$41.51M	$41.77M	$51.87M	$124.14M	$97.96M	$97.79M
Total Liabilities	$290.46M	$332.74M	$455.60M	$576.73M	$547.71M	$564.05M
Retained Earnings	-$589.13M	-$631.44M	-$888.67M	-$921.79M	-$965.06M	-$1.08B
Shareholders' Equity	-$211.48M	-$248.99M	-$176.94M	-$207.78M	-$249.22M	-$308.32M
Working Capital	-$247.04M	-$272.26M	-$342.46M	-$445.29M	-$459.78M	-$476.01M
Net Debt	$33.64M	$35.77M	$49.27M	$104.30M	$80.20M	$82.47M

SCLX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$6.01M	$7.05M	$8.23M	-$17.47M	-$1.11M	-$6.74M
Capital Expenditure	-$150.00K	-$150.00K	-$350.00K	-$83.00K	-$3.05M	—
Free Cash Flow	$5.86M	$6.90M	$7.88M	-$17.55M	-$4.16M	-$4.58M
Depreciation & Amortisation	$1.00M	$1.01M	$1.02M	$1.59M	$2.87M	$2.84M
Stock-Based Compensation	$3.31M	$3.28M	$3.26M	$5.64M	$3.63M	$3.60M
Investing Cash Flow	-$395.00K	-$153.00K	-$152.00K	$4.78M	-$9.16M	$8.45M
Financing Cash Flow	-$3.08M	-$8.60M	-$11.30M	$17.52M	$9.14M	-$4.48M
Net Change in Cash	$2.53M	-$1.70M	-$3.22M	$4.83M	-$1.12M	-$2.77M

Market Snapshot

About

Scilex Holding Company is a commercial-stage pharmaceutical company focused on acquiring, developing, and commercializing non-opioid pain management products. The company aims to address the unmet needs of patients suffering from acute and chronic pain.